IMPORTANT CORPORATE ANNOUNCEMENTS-1 - From 07.04.15 TO 10.04.15

CORPORATE ANNOUNCEMENTS -1

Here are some interesting Corporate announcements of the last Few days. As we can see, these announcements will have impact on the future performance of the companies concerned and hence, are important for investors.

10.04.2015

·       Aurobindo Pharma Limited has informed the Exchange vide letter dated April 10, 2015 that "Aurobindo Pharma Limited (APL) has divested its step-down subsidiary, Aurobindo Pharma {Australia) Pty Ltd to Eris Pharma Australia Pty Ltd. APL will, however, under an agreement continue to manufacture and supply the products to Eris Pharma for Australian and New Zealand market over next few years . This divestment is in line with APL's Strategy of focusing on US, EU and Key Emerging Markets. This subsidiary was not contributing any profit to Aurobindo.

·       Glenmark Pharmaceuticals Limited has informed the Exchange regarding the press release dated April 10, 2015 titled, "Glenmark Generics receives ANDA approval for Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.09 mg/0.02 mg."

·       Indusind Bank Limited has informed the Exchange regarding a press release dated April 10, 2015, titled "Indusind Bank enters into an agreement to acquire Royal Bank of Scotland's Diamond & Jewellery Financing business in India; simultaneously enters into Partnership Agreement with ABN AMRO Bank N.V. for cooperation in Diamond & Jewellery Financing".

09.04.15

·       Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 09, 2015 "Aurobindo Pharma receives USFDA Approval for Atracurium Besylate Injections".

·       Man Infraconstruction Limited has informed the Exchange regarding Press Release dated April 9, 2015, titled "Man Infraconstruction Ltd. receives order worth Rs. 105 Crore from Gujarat Pipavav Port Ltd.".

·       Kalpataru Power Transmission Limited has informed the Exchange regarding a press release dated April 9, 2015 titled "Company Commences Commercial Operations of Satpura Transmission Line Boot Project".

·       The Exchange had sought clarification from Aurobindo Pharma Limited with respect to a news item captioned "Aurobindo pharma alleges fraud by owners of Natrol bought by the company from Plethico pharma, contracts worth $25mn. were fictitious". The Company has submitted its clarification to above news .

·       Cipla Limited has informed the Exchange vide letter dated April 08, 2015 that " Cipla (EU) Limited, U.K., a wholly owned subsidiary of the Company, has entered into a definitive agreement for acquisition of 100% stake in Duomed Produtos Farmaceuticos Ltda. ("Duomed"), a limited liability company in Brazil for a cash consideration of Brazilian Real (R$) 1,293,600 (approx. INR 2.6 crores). Duomed was incorporated on 10th June 2013. It has in place approval of ANVISA (Brazilian health authority) and other regulatory authorities to import and distribute pharmaceutical products in Brazil. The acquisition is part of Company's front-end strategy and will expedite its product registrations in Brazil. None of the persons belonging to promoter/ promoter group(s) of the Company has any interest in the transaction and it is not a related party transaction for the Company. The transaction is expected to be completed by end of May 2015, subject to certain closing deliverables.

08.04.2015

·  ·       Glenmark Pharmaceuticals Limited has informed the Exchange that : "This is to inform you that our subsidiary Glenmark Generics Inc., USA has concluded the pricing investigation by the Texas Attorney General, USA. Under the terms of the agreed settlement, there is no admission of liability. Glenmark Generics will make a payment in 16 equal payments of $1.56 mn each quarter for the next 16 quarters to the state of texas. "The settlement amount will not materially impact the organization's cashflow". said Robert Matsuk, President, North America and Global API Business, Glenmark. "We remain committed to continuing our mission of providing our customers with the finest generic pharmaceutical products in the US and complying with all applicable state and federal pricing requirements." Under the settlement agreement, Glenmark must pay the State of Texas a total of $11.25 million for the State's general revenue fund. Because the Medicaid program is jointly funded by the State and U.S. taxpayers, the federal government is entitled to a percentage of the settlement proceeds. The federal government's share is also $11.25 million. Additionally, the Texas Attorney General's Office will receive $2.5 million in attorneys fees and costs."

·       icici Bank has announced a reduction of 0.25% in its Base Rate wef 10.04.15.Revised rate is 9.75%

07-04-2015

·       Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated April 07, 2015 titled "Dr. Reddy's Laboratories and its subsidiary Promius PharmaTM announce the filing of three NDAs with the USFDA".

·       Supreme Infrastructure India Limited has informed the Exchange that the Company has bagged the EPC work of Rs. 207.15 Crores of National Highways Authority of India (NHAI). The EPC project consists of 4 Laning of Kharar-Kurali Section of NH-21 from km 15.765 to km 29.900 (Design Chainages) (New NH-205) in the State of Punjab. The above contract is the cash contract with the Interest free advance payment from NHAI up to 10% of the contract price.

·       Fortis Healthcare Limited has informed the Exchange regarding a Press Release dated April 07, 2015 titled "Fortis Completes Sale of its Singapore Hospital to Concord Medical Services (International) Pte Ltd Receives SGD 55 Mn".

·   ·       Bharat Heavy Electricals Limited has informed the Exchange regarding a press release titled " BHEL expends its offerings, secures 89% EPC based power projects thereby retaining its leadership position with 72% market share for the consecutive year; BHEL Synchronized/commissioned 11,941 MW of power plant equipment more than 10,000 MW - 3rd year in a row. With this BHEL joined the elite club of select global giants having an installed base of over 150 GW of power generating equipment".

·       Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 07, 2015, titled "Glenmark receives final ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/2.5 mcg and 1 mg/5 mcg".